Covid-19 vaccine: AstraZeneca to develop Imperial's new RNA technology

Under the deal, VaxEquity, a start-up founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met

AstraZeneca Covid-19 vaccine, AstraZeneca — AstraZeneca's Covid-19 vaccine | Photo: Bloomberg

1 min read Last Updated : Sep 23 2021 | 10:43 PM IST

AstraZeneca on Thursday struck a deal with the firm behind Imperial College London's experimental Covid-19 vaccine to develop and sell drugs based on its self-amplifying RNA technology platform in other disease areas.

Under the deal, VaxEquity, a start-up founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met, in addition to royalties on approved drugs and equity investment from AstraZeneca.